Pacira Enterprise Value Over E B I T D A from 2010 to 2025
| PCRX Stock | USD 24.14 0.32 1.34% |
Enterprise Value Over EBITDA | First Reported 2010-12-31 | Previous Quarter 37.24427502 | Current Value 41.32 | Quarterly Volatility 164.03919127 |
Check Pacira BioSciences, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pacira BioSciences,'s main balance sheet or income statement drivers, such as Depreciation And Amortization of 82.7 M, Interest Expense of 15.8 M or Selling General Administrative of 67.3 M, as well as many indicators such as Price To Sales Ratio of 1.18, Dividend Yield of 0.0014 or PTB Ratio of 1.06. Pacira financial statements analysis is a perfect complement when working with Pacira BioSciences, Valuation or Volatility modules.
Pacira | Enterprise Value Over E B I T D A |
Latest Pacira BioSciences,'s Enterprise Value Over E B I T D A Growth Pattern
Below is the plot of the Enterprise Value Over E B I T D A of Pacira BioSciences, over the last few years. It is Pacira BioSciences,'s Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pacira BioSciences,'s overall financial position and show how it may be relating to other accounts over time.
| Enterprise Value Over E B I T D A | 10 Years Trend |
|
Enterprise Value Over E B I T D A |
| Timeline |
Pacira Enterprise Value Over E B I T D A Regression Statistics
| Arithmetic Mean | 42.87 | |
| Coefficient Of Variation | 382.65 | |
| Mean Deviation | 82.44 | |
| Median | 27.07 | |
| Standard Deviation | 164.04 | |
| Sample Variance | 26,909 | |
| Range | 794 | |
| R-Value | (0.08) | |
| Mean Square Error | 28,630 | |
| R-Squared | 0.01 | |
| Significance | 0.76 | |
| Slope | (2.88) | |
| Total Sum of Squares | 403,633 |
Pacira Enterprise Value Over E B I T D A History
About Pacira BioSciences, Financial Statements
Pacira BioSciences, investors use historical fundamental indicators, such as Pacira BioSciences,'s Enterprise Value Over E B I T D A, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Pacira BioSciences,. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Enterprise Value Over EBITDA | 37.24 | 41.32 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Pacira Stock Analysis
When running Pacira BioSciences,'s price analysis, check to measure Pacira BioSciences,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacira BioSciences, is operating at the current time. Most of Pacira BioSciences,'s value examination focuses on studying past and present price action to predict the probability of Pacira BioSciences,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacira BioSciences,'s price. Additionally, you may evaluate how the addition of Pacira BioSciences, to your portfolios can decrease your overall portfolio volatility.